Pepticom

Pepticom is a biotechnology company using artificial intelligence to streamline peptide drug discovery. Its algorithmic platform combines principles from economic and molecular mechanics to generate a wide scope of active molecules with higher success rates. In this way, Pepticom aims to lower the number of research and development candidates synthesized and tested, with a similar reduction in time and costs compared to traditional lab-based discovery methods. The use of computational technology allows Pepticom to address complex targets unreachable by laboratory methods and to further enhance research and development. The platform utilizes the structure of the target protein to design innovative peptides at atomic resolution. It is also capable of designing several peptides chemistry, including linear, helical, and cyclic peptides, and incorporating D and non-natural amino acids in the process. The company is involved in various successful discovery projects with academic and industry partners and has several molecules in different development stages. In March 2021, Pepticom established a spin-off company, PeptiCov, which will focus on developing treatments for the SARS-CoV-2 virus responsible for the COVID-19 outbreak.

Pepticom has raised $14.2M in total funding across 4 rounds. The company is currently at the A stage. Key investors include The Chartered Group, Galia Kut, Rachel Hamburger.

Pepticom was founded in 2011 by Immanuel Lerner (CEO, Co-Founder & Director ), Anwar Rayan (Co-Founder), Amit Michaeli (Co-founder & CTO).

Pepticom operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology.

Pepticom is based in Professor Racah St, Jerusalem, Israel, Jerusalem District.